Protagenic’s PT00114 Breakthrough: New Hope for Stress Disorders
Protagenic Therapeutics achieves milestone in Phase I trial for PT00114, a compound for treating stress-related neuro-psychiatric disorders. No adverse reactions ...
- Latest
- Trending
Protagenic Therapeutics achieves milestone in Phase I trial for PT00114, a compound for treating stress-related neuro-psychiatric disorders. No adverse reactions ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.